Natural Remedies, a leading herbal extract innovator and manufacturer, announces the successful completion and publication of second clinical trial on its brand GutGard®, which is a patent pending, flavanoid-rich plant extract derived from Glycyrrhiza glabra roots. The study titled “Effect of GutGard® in the Management of Helicobacter pylori -A Randomized Double Blind Placebo Controlled Study” is published in peer reviewed scientific journal Evidence-Based Complementary and Alternative Medicine (ECAM), (Volume 2013, Article ID 263805). The journal is PubMed reviewed and also indexed in PubMed and Science Citation Index Expanded with an impact factor of 4.774.
In the present double-blind, placebo-controlled trial, supplementation of GutGard for 60 days resulted in significant difference in gastric Helicobacter pylori load between GutGard and placebo-treated groups. Also, GutGard was found to be 73.2 percent, or 3.73 times, more effective than placebo.
GutGard has already undergone in vivo and clinical studies, which have proved GutGard to be safe and efficacious for managing the symptoms of functional dyspepsia. A recently published in vitro study on Gutgard revealed its mechanism of anti-Helicobacter pylori activity, possibly through inhibition of bacterial protein synthesis, DNA gyrase and dihydrofolate reductase.
The director of research at Natural Remedies, Dr. Amit Agarwal, said that “GutGard supplementation can be considered as an effective alternate option for the management of Helicobacter pylori. GutGard, with its low dose (150mg/person/day), is a preferred functional food ingredient for variety of applications.”